Mood stabilizers in pregnancy and lactation

Area of Science:

• Perinatal Psychiatry
• Pharmacology in Pregnancy
• Neurodevelopmental Disorders

Background:

• Bipolar disorder management during pregnancy presents significant challenges.
• Clinicians must balance maternal mental health with fetal safety.
• Individualized treatment plans are crucial, considering patient history and medication response.

Purpose of the Study:

• To review the safety and efficacy of psychotropic medications for bipolar disorder during pregnancy and postpartum.
• To provide guidance on medication selection based on trimester and lactation.
• To highlight risks associated with specific mood stabilizers.

Main Methods:

• Literature review of studies on psychotropic medication use in pregnant and lactating women with bipolar disorder.
• Analysis of safety and efficacy data for mood stabilizers and antipsychotics.
• Evaluation of risks, including major malformations and developmental sequelae.

Main Results:

• Lithium use in the second and third trimesters appears safe.
• Valproate and carbamazepine in the first trimester are associated with major malformations and developmental issues.
• Lamotrigine (LTG) shows a more favorable profile compared to other antiepileptics.
• Typical and atypical antipsychotics are viable options during pregnancy.
• Valproate and LTG are considered safe during lactation.

Conclusions:

• Medication choice for bipolar disorder in pregnancy necessitates a risk-benefit assessment.
• Certain mood stabilizers carry significant risks, particularly in the first trimester.
• Close monitoring and individualized care are essential for optimal outcomes.